PharmaLive: Cytos Biotechnology Enters Exclusive License Agreement With Novartis to Develop, Manufacture and Commercialize Novel Vaccine for Treatment

PharmaLive: Cytos Biotechnology Enters Exclusive License Agreement With Novartis to Develop, Manufacture and Commercialize Novel Vaccine for Treatment of Nicotine Addiction: "ZURICH , Switzerland, April 25, 2007 /PRNewswire-FirstCall/ -- Cytos Biotechnology AG announced today that it has entered into an exclusive global commercial license agreement with Novartis to develop, manufacture and commercialize CYT002-NicQb, a therapeutic vaccine in phase II clinical development for the treatment of nicotine addiction."